 |
|
|
| | | | | | Dear colleagues,
| | | | | | | | We are committed to a safe ISHL12 during these challenging times. In order to ensure the usual interactive participation of all interested hematologists worldwide, the ISHL team is currently planning a hybrid event from October 22 to 24, 2022.
| | | | | | | | We know you are eager to participate in-person, to network with colleagues, discuss the latest scientific advances and groundbreaking research presentations and experience the symposia, exhibit and posters. As the safety of our attendees is our top priority, proof of being fully vaccinated against COVID-19 will be required for in-person participation. Further, detailed specifications will be provided in due time before our congress. Depending on the situation in October 2022 and requirements by German regulations, additional COVID-19 testing requirements might apply.
| | | | | | | | However, we also know that some of you will hesitate or not be able to attend in-person. If you fall into that group, be assured that we also want you to have the best possible ISHL experience. Therefore, a hybrid event with the possibility of both in-person and online attendance is in our view the best way forward.
| | | | | | | | ISHL12 will provide a comprehensive overview on the latest advances in biology, clinical research, diagnostics and treatment of Hodgkin Lymphoma. A main focus will be on older and frail patients and on patients with early stages. Several workshops, interactive case discussions and satellite symposia will complement the program.
| | | | | |
|
|
|
|
|
